KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Common Equity (2016 - 2025)

Sarepta Therapeutics has reported Common Equity over the past 16 years, most recently at $1.1 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 25.34% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 25.34%, while the annual FY2025 figure was $1.1 billion, 25.34% down from the prior year.
  • Common Equity for Q4 2025 was $1.1 billion at Sarepta Therapeutics, down from $1.3 billion in the prior quarter.
  • Over five years, Common Equity peaked at $1.5 billion in Q4 2024 and troughed at $385.0 million in Q4 2022.
  • A 5-year average of $882.2 million and a median of $858.1 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 58.52% in 2022 and later surged 123.23% in 2023.
  • Year by year, Common Equity stood at $928.0 million in 2021, then crashed by 58.52% to $385.0 million in 2022, then skyrocketed by 123.23% to $859.3 million in 2023, then surged by 77.78% to $1.5 billion in 2024, then fell by 25.34% to $1.1 billion in 2025.
  • Business Quant data shows Common Equity for SRPT at $1.1 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.4 billion in Q2 2025.